-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the characteristics of humanized model of immune system?
Author:
InnoModels
Release time:
2024-05-15
As a specialized, special and new enterprise in Beijing, InnoModels Biotechnology (Beijing) Co., Ltd. has been working in the field of humanized models of the immune system since its establishment, and has continuously promoted the research, development and application of related technologies. The humanized immune system model developed by the company has successfully rebuilt the human immune system in mice by transplanting human immune cells or precursor cells into mice, providing unprecedented experimental means for drug research and development, tumor immunotherapy and other fields.
The humanized immune system model of InnoModels has remarkable features. Firstly, it realizes the stable reconstruction of the immune system. Traditional animal models are often difficult to fully simulate the human immune system, resulting in large discrepancies between experimental results and clinical data. However, the modeling success rate of the biomimetic model has been improved from 50% to 87%, and the coefficient of variation within the group has also been greatly reduced, which makes the experimental results more reliable and stable.
Secondly, the model of InnoModels is able to reconstruct multiple immune cells. In previous models, only T-cells can be successfully reconstructed in mice. However, the model breaks through this limitation and can reconstruct a variety of immune cells, including T cells, B cells, NK cells, macrophages, DC cells, etc., thus more realistically simulating the complexity of the human immune system.

In addition, the number of immune cells reconstructed in the model of InnoModels Biotechnology can reach or approach the concentration of human immune cells. This means that the model can provide a more realistic environment for drug testing, enabling drugs to be evaluated under conditions closer to the actual human condition before entering clinical trials, thus improving the efficiency and success rate of drug development.
In order to meet the needs of different fields, InnoModels Biotechnology also provides customers with several sub-platforms. Among them, the iHuPBMC-T platform is designed for T-cell immunotherapy, which is able to simulate the behavior of human T-cells in the tumor microenvironment, providing strong support for T-cell immunotherapy research and development. In addition, InnoModels Biotechnology has also launched the PBMC-PDX Dual Derivative Model, which can be modeled using tumors and PBMCs originating from the same patient, making the experimental results closer to the clinical reality.
It is worth mentioning that InnoModels' PBMC-PDX model has successfully solved the major problems of tumor growth and PBMC antagonism and cycle matching in immune system tumor models, significantly improving the success rate of experiments and overcoming the problem of short drug delivery window due to graft-versus-host disease. This makes the model have higher application value in the development of tumor immunity drugs.
Overall, the humanized model of the immune system of InnoModels Biotechnology shows great potential in the fields of drug discovery and tumor immunotherapy due to its stability, multicellular reconstruction, and proximity to human body concentration. Meanwhile, the multiple sub-platforms it provides also meet the needs of different fields, providing scientists with richer and more efficient experimental means. It is believed that in the future, InnoModels Biotechnology will continue to make innovations and breakthroughs in the field of humanized models of the immune system, and make greater contributions to the cause of human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd